What is claimed is:

1. A pharmaceutical composition comprising:
   (a) a hydrochloride salt of transnorsertraline or a hydrate thereof;
   (b) mannitol; and
   (c) one or more of
      (i) a disintegrant;
      (ii) a lubricant; and
      (iii) an anti-caking agent.

2. The pharmaceutical composition of claim 1, wherein the disintegrant is selected from the group consisting of croscarmellose sodium and sodium starch glycolate.

3. The pharmaceutical composition of claim 1, wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate and stearic acid.

4. The pharmaceutical composition of claim 1, wherein the anti-caking agent is selected from the group consisting of talc, kaolin or bentonite.

5. The pharmaceutical composition of any one of claims 1 to 4 which is in tablet or capsule form.

6. The pharmaceutical composition of any one of claims 1 to 4, wherein the composition comprises at least 10% by weight of mannitol.

7. Use of a composition of any one of claims 1 to 6 in the manufacture of a medicament for treating, or preventing, or managing a neurological disorder.

8. The use of claim 7, wherein the neurological disorder is selected from the group consisting of depression, cognitive deficits, fibromyalgia, pain, a sleep related disorder, chronic fatigue syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), restless leg syndrome, schizophrenia, anxiety, obsessive compulsive disorder, posttraumatic stress disorder, seasonal affective

disorder (SAD), premenstrual dysphoria, post-menopausal vasomotor symptoms, a neurodegenerative disease, manic conditions, dysthymic disorder, cyclothymic disorder, obesity, and substance abuse or dependency.

9. A pharmaceutical composition comprising a hydrochloride salt of transnorsertraline or a hydrate thereof, mannitol, magnesium stearate, talc and sodium starch glycolate.

10. The pharmaceutical composition of claim 9 which is in tablet or capsule form.

11. The pharmaceutical composition of claim 9, wherein the composition comprises at least 10% by weight of mannitol.

12. Use of a compound or composition of any one of claims 9 to 11 in the manufacture a medicament for treating, or preventing or managing a neurological disorder.

13. The use of claim 12, wherein the neurological disorder is selected from the group consisting of depression, cognitive deficits, fibromyalgia, pain, a sleep related disorder, chronic fatigue syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), restless leg syndrome, schizophrenia, anxiety, obsessive compulsive disorder, posttraumatic stress disorder, seasonal affective disorder (SAD), premenstrual dysphoria, post-menopausal vasomotor symptoms, a neurodegenerative disease, manic conditions, dysthymic disorder, cyclothymic disorder, obesity, and substance abuse or dependency.

What is claimed is:

1. A pharmaceutical composition comprising transnorsertraline or pharmaceutically acceptable salt or solvate thereof, and mannitol or xylitol.

2. The pharmaceutical composition of claim 1, further comprising talc, kaolin or bentonite.

3. The pharmaceutical composition of claim 2, further comprising magnesium stearate, calcium stearate, zinc stearate, or stearic acid.

4. The pharmaceutical composition of claim 1, wherein the composition comprises a hydrochloride salt of transnorsertraline or a hydrate thereof, mannitol, magnesium stearate, talc and sodium starch glycolate.

5. The pharmaceutical composition of claim 1 which is in tablet or capsule form.

6. The pharmaceutical composition of claim 1, wherein the composition comprises at least 10% by weight of mannitol or xylitol.

7. The pharmaceutical composition of claim 1, wherein the composition comprises at least 10% by weight of mannitol.

8. A crystalline hydrochloride salt of transnorsertraline or a hydrate thereof, which has an X-ray powder diffraction pattern comprising peaks at about 14.9, 17.8, 19.2, 23.3, 24.6 and 25.2 degrees 2θ.

9. The salt of claim 8 which has an X-ray powder diffraction pattern further comprising peaks at about 5.0 and 21.8 degrees 2θ.

10. The salt of claim 9 which has a calculated X-ray powder diffraction pattern comprising peaks at about 5.1, 15.0, 18.0, 19.5, 22.0 23.5, 24.8 and 25.4 degrees 2θ, based on data collected at about 173K on a single crystal.

11. The salt of claim 9 which has the following approximate unit cell dimensions: a = 16.8 Å, b = 5.2 Å, c = 19.1 Å, α = 90.0°, β = 113.1° and γ = 90.0°.

12. The salt of claim 9 which has the following approximate unit cell dimensions when measured at about 173K:
a = 16.83 Å, b = 5.23 Å, c = 19.06 Å, α = 90.00°, β = 113.10° and γ = 90.00°.


13. The salt of claim 12 wherein the approximate unit cell dimensions are:
a = 16.834 Å, b = 5.226 Å, c = 19.059 Å, α = 90.00°, β = 113.10° and γ = 90.00°.

14. The salt of claim 11 which has the space group *C*2 (no. 5).

15. The salt of claim 11 wherein the unit cell contains four transnorsertraline hydrochlorides (*Z* = 4).


16. The salt of claim 8 which has a density of about 1.4 g cm^{-3}.

17. The pharmaceutical composition of claim 1, wherein the composition comprises less than about 3 % by weight of a compound of formula (II):



(II)

18. The pharmaceutical composition of claim 1, wherein the composition comprises less than about 4 % by weight of compounds of formula (III):



(III)

~~Use of a compound or composition of any one of claims 1-18, in the manufacture of a~~ medicament for treating, preventing or managing a neurological disorder.

20. The use of claim 19, wherein the neurological disorder is depression, cognitive deficits, fibromyalgia, pain, a sleep related disorder, chronic fatigue syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), restless leg syndrome, schizophrenia, anxiety, obsessive compulsive disorder, posttraumatic stress, disorder, seasonal effective disorder (SAD), premenstrual dysphoria, post-menopausal vasomotor symptoms, a neurodegenerative disease, manic conditions, dysthymic disorder, cyclothymic disorder, obesity, or substance abuse or dependency.